Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03070353

Enrollment

Registered

2017-03-03

Start date

2015-07-01

Completion date

2016-06-30

Last updated

2017-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, Liver, AKI

Keywords

Cirrhosis, AKI, Albumin, Dextran

Brief summary

A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI

Detailed description

A pilot study of Dextran-40 infusion in decompensated cirrhotic patients complicating with AKI. Dextran-40® was administered at 1 g/kg/day for two days. AKI reversal was defined when serum creatinine was \< 1.5 mg/dL. Albumin infusion was given if AKI reversal did not occur.

Interventions

DRUGDextran 40

Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Focus on clinical response after receiving treatment

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Decompensated cirrhosis with acute kidney injury * Ager over 18 years old

Exclusion criteria

* Having chronic kidney disease, severe heart or lung disease, severe sepsis * Pregnant * Receiving nephrotoxic agents * Having history of allergic to Dextran

Design outcomes

Primary

Measure	Time frame	Description
AKI reversal	2 weeks	Reducing creatinine to below 1.5 mg/dl

Secondary

Measure	Time frame	Description
Mortality	1 year	Death

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026